Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs), today announced ...
Patients in a Phase I/II clinical trial conducted by UMass Chan Medical School of a dual vector gene therapy for GM2 gangliosidosis, which includes Tay-Sachs and Sandhoff diseases, exhibited a ...
A new gene-editing technique enables the correction of multiple genetic mutations simultaneously, transforming the prospects for millions living with complex inherited diseases, such as cystic ...
National Tay-Sachs and Allied Diseases Association Dedicated to research treatment and prevention. Information and services to individuals and families. Public and professional education, research, ...
Some genetic disorders-such as cystic fibrosis, hemophilia and Tay Sachs disease-involve many mutations in a person's genome, often with enough variation that even two individuals who share the same ...
Zeng, B. J., Torres, P. A., Viner, Tabitha, Wang, Z. H., Raghavan, S. S., Alroy, J., Pastores, G. M., and Kolodny, E. H. 2008. "Spontaneous Appearance of Tay-Sachs ...
Early genetic counseling gives families crucial information and support, turning uncertainty about rare diseases into informed decisions, community connections and hope for their children’s health and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results